The Cooper Companies, Inc. (COO) Quarterly Net Income
The quarterly net income for The Cooper Companies, Inc. (COO) is ($77.90M) with a period-over-period change of (159.56%). Quarterly net income is profit after expenses, taxes, interest, and other items for the latest fiscal quarter.
COO Quarterly Net Income Chart
Quarterly Net Income History
| Date | Quarterly Net Income | % Change |
|---|---|---|
| Q2 2026 | ($77.90M) | (159.56%) |
| Q1 2026 | $130.80M | +54.61% |
| Q4 2025 | $84.60M | (13.94%) |
| Q3 2025 | $98.30M | +12.09% |
| Q2 2025 | $87.70M | (15.92%) |
| Q1 2025 | $104.30M | (11.23%) |
| Q4 2024 | $117.50M | +12.23% |
| Q3 2024 | $104.70M | +17.77% |
| Q2 2024 | $88.90M | +9.48% |
| Q1 2024 | $81.20M | (3.91%) |
| Q4 2023 | $84.50M | (0.94%) |
| Q3 2023 | $85.30M | +114.32% |
| Q2 2023 | $39.80M | (52.96%) |
| Q1 2023 | $84.60M | +28.96% |
| Q4 2022 | $65.60M | (33.33%) |
| Q3 2022 | $98.40M | (22.27%) |
| Q2 2022 | $126.60M | +32.84% |
| Q1 2022 | $95.30M | (13.60%) |
| Q4 2021 | $110.30M | (82.09%) |
| Q3 2021 | $615.80M | +424.09% |
| Q2 2021 | $117.50M | (94.41%) |
| Q1 2021 | $2.10B | +2487.56% |
| Q4 2020 | $81.20M | +47.10% |
| Q3 2020 | $55.20M | +380.00% |
| Q2 2020 | $11.50M | (87.29%) |
| Q1 2020 | $90.50M | (25.21%) |
| Q4 2019 | $121.00M | +0.75% |
| Q3 2019 | $120.10M | (1.88%) |
| Q2 2019 | $122.40M | +18.60% |
| Q1 2019 | $103.20M | +2.58% |
| Q4 2018 | $100.60M | (0.20%) |
| Q3 2018 | $100.80M | +65.52% |
| Q2 2018 | $60.90M | +149.71% |
| Q1 2018 | ($122.50M) | (238.26%) |
| Q4 2017 | $88.60M | (14.48%) |
| Q3 2017 | $103.60M | (1.24%) |
| Q2 2017 | $104.90M | +38.39% |
| Q1 2017 | $75.80M | +25.27% |
| Q4 2016 | $60.51M | (31.18%) |
| Q3 2016 | $87.93M | +18.62% |
| Q2 2016 | $74.13M | +44.34% |
| Q1 2016 | $51.36M | +40.01% |
| Q4 2015 | $36.68M | (18.40%) |
| Q3 2015 | $44.95M | (25.96%) |
| Q2 2015 | $60.71M | (0.76%) |
| Q1 2015 | $61.18M | +98.72% |
| Q4 2014 | $30.79M | (65.04%) |
| Q3 2014 | $88.07M | +11.25% |
| Q2 2014 | $79.16M | +10.18% |
| Q1 2014 | $71.84M | +25.17% |
| Q4 2013 | $57.40M | (35.47%) |
| Q3 2013 | $88.95M | +18.39% |
| Q2 2013 | $75.14M | +0.63% |
| Q1 2013 | $74.67M | +3.82% |
| Q4 2012 | $71.92M | +7.54% |
| Q3 2012 | $66.88M | +21.77% |
| Q2 2012 | $54.92M | +0.55% |
| Q1 2012 | $54.62M | (3.56%) |
| Q4 2011 | $56.64M | +48.51% |
| Q3 2011 | $38.14M | +7.85% |
| Q2 2011 | $35.36M | (21.93%) |
| Q1 2011 | $45.30M | (6.02%) |
| Q4 2010 | $48.20M | +21.32% |
| Q3 2010 | $39.73M | +791.54% |
| Q2 2010 | $4.46M | (78.18%) |
| Q1 2010 | $20.42M | (32.19%) |
| Q4 2009 | $30.12M | +37.47% |
| Q3 2009 | $21.91M | (11.12%) |
| Q2 2009 | $24.65M | +3.25% |
| Q1 2009 | $23.87M | (19.02%) |
| Q4 2008 | $29.48M | +64.88% |
| Q3 2008 | $17.88M | +59.05% |
| Q2 2008 | $11.24M | +63.46% |
| Q1 2008 | $6.88M | +128.43% |
| Q4 2007 | ($24.19M) | (395.76%) |
| Q3 2007 | $8.18M | +1652.18% |
| Q2 2007 | ($527,000) | (109.85%) |
| Q1 2007 | $5.35M | (60.68%) |
| Q4 2006 | $13.60M | (35.16%) |
| Q3 2006 | $20.98M | +53.11% |
| Q2 2006 | $13.70M | (23.69%) |
| Q1 2006 | $17.95M | +181.85% |
| Q4 2005 | $6.37M | (82.95%) |
| Q3 2005 | $37.36M | +26.59% |
| Q2 2005 | $29.51M | +59.63% |
| Q1 2005 | $18.49M | (35.64%) |
| Q4 2004 | $28.72M | +19.44% |
| Q3 2004 | $24.05M | +10.83% |
| Q2 2004 | $21.70M | +18.22% |
| Q1 2004 | $18.36M | (12.77%) |
| Q4 2003 | $21.04M | +12.74% |
| Q3 2003 | $18.66M | +22.69% |
| Q2 2003 | $15.21M | +9.79% |
| Q1 2003 | $13.86M | (14.43%) |
| Q4 2002 | $16.19M | +21.18% |
| Q3 2002 | $13.36M | - |
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White